S and Precautions For use in Kinesin Spindle Protein dienogest. Women with uterine fibroids and adenomyosis are more likely to have heavy menstrual bleeding. One study examined hormonal and histological properties of irregularly for take-genital bleeding in patients may need during the treatment of endometriosis dienogest. This study showed that irregular Owned bleeding genitals w During dienogest treatment, the cause of the bleeding pseudodecidua, which was developed by a direct effect of progestin dienogest. The authors have also shown that none of the serum hormonal Ver were Changes irregularly with the occurrence of irregular Strength genital bleeding bleeding.10 However, the study Strength genital h Frequently from patients w During dienogest treatment of endometriosis occur, and focus on it correlates is unclear whether these results apply to heavy uterine bleeding in patients with adenomyosis. According to our knowledge little about the mechanism that caused heavy menstrual bleeding in patients treated with dienogest known adenomyosis. In general, the enlarged Erte building Rmutter with L Emissions that must be made of adenomyosis and endometrial volume increase as one of the reasons for the increased Hte amount of menstrual bleeding in adenomyosis patients.11 It is well known that mild to m suppressed ig estradiol in patients with Gn RH agonists increased occurrence ht of irregular for take-bleeding in the genital area of a wehypothesized strongly suppressed estradiol.12 therefore, that the size e of the uterus and the levels of estradiol on the effects treated similar to uterine bleeding in patients with adenomyosis. We also hypothesized that the age of estradiol and dienogest may need during the treatment with the occurrence of uterine bleeding affects searches. Based on these assumptions, we invested the factors that influence the treatment of uterine bleeding w During dienogest. The aim of this study was to determine risk factors for discontinuation because of uterine bleeding in patients with adenomyosis treated with dienogest. Avoided by identifying the high risk group and the treatment of these patients dienogest cliniciansmay be able to reduce the incidence of discontinuation due to menstrual bleeding. Materials and Methods Patients Patients with adenomyosis, the dienogest treatment between M March 2008 and September 2009, the Department of Gyn Ecology and obstetrics began were the Jikei University t H and the Pital YEARS-Engine included in the study institution. The patients were administered dienogest in a dose of 2 mg / day. Adenomyosis was best by diagnostic imaging such as ultrasound and magnetic resonance imaging CONFIRMS. The data on patient 鈥 Demographics were obtained characteristics of the disease course and laboratory and diagnostic imaging results retrospectively from medical records. Statistical analysis Statistical analyzes were performed with SAS 9.3. We focused on stopping treatment because of menstrual bleeding and a prim Ren endpoint. Patients who discontinued treatment due to side effects au He menstrual bleeding or non-medical reasons, and patients who were lost to follow-up were censored as F Ll treated. Age, the sagittal area of the square building Rmutter before treatment and estradiol in the third month of treatment were selected for potential risk factors selected. In front of me.